In this issue of *Neurology*® *Neuroimmunology & Neuroinflammation*, Salzberg et al^[@R1]^ report on the results of a small prospective study of the application of next-generation sequencing (NGS) of RNA and DNA extracted from brain biopsy tissue specimens obtained from 10 patients with suspected neuroinfectious disease processes. In 3 patients, the NGS results, which included JC virus, Epstein-Barr virus, and *Mycobacterium tuberculosis*, were validated by other measures. Standard diagnostic methods would have led to the correct diagnosis in these patients; however, the NGS results showed that the same conclusions could have been drawn from a single assay that is able to detect bacteria, fungi, parasites, and viruses simultaneously. In 2 patients, the NGS results were indeterminate, but raised the possibility of infectious organisms that had not been suspected clinically: possible *Delftia acidovorans* in a 69-year-old man with Tolosa-Hunt syndrome and pachymeningitis and *Elizabethkingia spp.* from the brain mass of a 19-year-old man with Fanconi anemia.^[@R1]^ In 5 other cases, the investigators found NGS clinically useful, such as ruling out the presence of an infection in suspected cases of sarcoidosis or glial tumors,^[@R1]^ although the actual negative predictive value of a negative NGS result awaits definition in a larger prospective study.

The cost of performing NGS and analyzing the data, which can be accomplished in as little as 48 hours,^[@R2]^ is currently estimated at \$2,000--\$5,000/sample and will almost certainly continue to decline with refinements in methodology and advances in sequencing technology. NGS has broad potential applications, including the identification of pathogens, improving tumor classification,^[@R3],[@R4]^ identifying genetic disorders in newborns,^[@R5]^ and a myriad of other potential applications. The use of NGS in identifying difficult-to-diagnose infectious diseases of the nervous system has included the identification of such pathogens as *Leptospria spp.*^[@R2]^ and *Balamuthia mandrillaris*^[@R6]^ in the CSF of patients with meningoencephalitis. A novel astrovirus,^[@R7],[@R8]^ variegated squirrel bornavirus,^[@R9]^ and *M tuberculosis*^[@R10]^ have also been identified in solid tissue specimens, including brain biopsies. This series adds to this small but growing literature.

Infectious diseases of the nervous system are often difficult to diagnose. Although most meningitis results from an infectious pathogen, epidemiologic studies suggest that the causative organism remains undetected in between 15% and 60% of cases.^[@R11][@R12][@R13]^ Similarly, there are more than 100 infectious pathogens that have been associated with encephalitis,^[@R14]^ but in only 40%--70% is an etiology established.^[@R15][@R16][@R17]^ The relatively high number of patients in whom a pathogen cannot be identified has been attributed to suboptimal testing and a lack of tests for all the potential pathogens.^[@R16]^ Frequently, empiric treatment is instituted despite the absence of an identified pathogen, resulting in inadequate or inappropriate treatment and potentially dangerous delays in diagnosis.

Despite the higher yield in recognizing infectious pathogens from brain and spinal abscesses, even the availability of tissue does not ensure a diagnosis.^[@R18]^ Some series state that stereotactic biopsy is nondiagnostic in 2%--15% of patients,^[@R19]^ but in one recent series of 100 patients undergoing stereotactic biopsy, 24 specimens proved to be nondiagnostic.^[@R20]^ Smaller lesions (\<1 cm^3^) have lower diagnostic yields.^[@R21]^ Often the nondiagnostic biopsy is the consequence of inadequate tissue sampling.

The application of NGS to these tissue specimens will almost certainly increase the ability to detect an offending microorganism, but the 2 indeterminate cases in this series also highlight the potential pitfalls of such a broad brush, hypothesis-free assay. Bacterial sequences are omnipresent in unbiased, metagenomic NGS datasets as a result of sample and laboratory contamination.^[@R22],[@R23]^ Indeed, *Delftia acidovorans* was present in the NGS results of a number of the other subjects in this case series, but in those cases, it was considered to be a contaminant. In addition, *Elizabethkingia spp.* frequently appears as a contaminant in metagenomic NGS datasets as well. Without a negative control like a water sample accompanying each sequencing run, it can be very difficult to discriminate between infection and contamination.

For metagenomic NGS to move from the research laboratory to the clinical laboratory, the field as a whole needs to develop rigorous criteria for determining whether a microbe present in the NGS data was an infection. The Food and Drug Administration recently issued guidance on this issue (<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM500441.pdf>). Indeed, identifying sequences in a dataset that align to a particular organism is only the start of the analysis. One must then investigate the specificity with which those reads align to that organism and not to any others. In addition, the extent of genomic coverage must be evaluated. A 100- to 200-nucleotide sequence aligning to an organism is much less convincing for infection than when one can find sequences covering much of the organism\'s genome. Finally, NGS is semiquantitative, and a high abundance of reads to an organism relative to the typical background levels seen in other samples can also be suggestive of a real infection vs contamination.^[@R24]^ Once the analysis of the NGS data was complete, orthogonal assays are critical for confirming the presence of a particular pathogen, including culture, 16s ribosomal RNA PCR, immunohistochemistry, serology, and, if appropriate, electron microscopy. Finally, placing all the results into the particular patient\'s clinical context is also crucial.

Because metagenomic NGS attempts to sequence all of the nucleic acid in a sample by using random hexamer primers, it may uncover totally unanticipated associations between diseases of unknown etiology and a specific pathogen. Examples of the latter that predate the NGS sequencing era include Whipple disease, now recognized to be the consequence of the bacterium *Tropheryma whipplei*,^[@R25]^ and tropical spastic paraparesis, recognized to be the consequence of a retrovirus, human T-lymphotropic virus (HTLV) type I^[@R26]^ (and less often, type II), and currently referred to as HTLV-associated myelopathy.

As the accessibility of NGS increases, there will almost certainly be a large and growing contingent of patients for whom NGS will be performed. The preliminary studies on brain tissue reported in this issue add to the existing literature and highlight the need for larger studies to rigorously characterize the performance characteristics of the assay across an array of tissue types and organisms.

[See article](http://nn.neurology.org/lookup/doi/10.1212/NXI.00000000000000251)
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